INBIOS INTERNATIONAL, INC.

InBios International, Inc. is a privately-held biotechnology company specializing in the design, development, and manufacture of immunodiagnostic devices for infectious diseases and biothreats. Founded in 1996 and headquartered in Seattle, Washington, the company operates a state-of-the-art GMP-compliant, FDA-registered manufacturing facility certified to ISO 13485:2016. InBios maintains a portfolio of over 25 FDA-cleared diagnostic products and extensive life science reagent catalogs. Core offerings include ELISA kits, rapid point-of-care tests, and contract manufacturing services for emerging infectious disease diagnostics. The company delivers immunoassays targeting dengue, West Nile virus, Zika, Chagas disease, leishmaniasis, COVID-19, influenza, and biothreats such as anthrax and melioidosis. InBios provides comprehensive assay development, regulatory affairs support, and contract manufacturing capabilities to clinical laboratories, public health agencies, research institutions, and OEM partners globally. The company is recognized for rapid response to emerging disease threats while maintaining rigorous quality standards and cost-effective solutions for the global diagnostic market.